Reply

Fonseca, Válter R.; Romão, Vasco C; Água-Doce, Ana; Fonseca, João Eurico; Graça, Luís

doi:10.1002/art.40487

Cited by 1 publication

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9][10][11][12] Abnormal immune responses and the imbalance of autoimmune homeostasis, such as, inhibition of regulatory T (Treg) cells and promotion of follicular helper T (Tfh) cells, contribute to pSS progression. [9,[13][14][15] The pathophysiological features of pSS comprise lymphocytic infiltration, deposition of immunocomplexes, and ectopic germinal center formation, which may be related to the abnormal proportion and function of Treg and effector T cell (Teff) cells, including Tfh and CD4 + IL-17A + helper T cell (Th17) (the CD4 + IL − 17A + helper T) cells. Tfh cells play an essential role in the humoral immune response, as well as, the formation of germinal center (GC) in secondary lymphoid organs and autoantibodies production.…”

Section: Introductionmentioning

confidence: 99%

“…Tfh cells play an essential role in the humoral immune response, as well as, the formation of germinal center (GC) in secondary lymphoid organs and autoantibodies production. [13,16,17] Treg cells are vital for protecting immune homeostasis via modulation of pathological immune responses and the induction of immune self-tolerance. The imbalance of Treg/Teff has been observed previously and is thought to be the key mechanism for disease initiation and progression in pSS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lycium barbarum Polysaccharide Ameliorates Sjögren's Syndrome in a Murine Model

Wang

Xiao

Duan

et al. 2021

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope This study aims to evaluate the therapeutic efficacy and mechanisms of Lycium barbarum polysaccharide (LBP) in primary Sjögren's syndrome (pSS). Methods and results Non‐obese diabetic mice (the pSS model) are randomly divided into four groups: Low dose LBP (LBP.L, 5 mg kg−1 d−1), high dose LBP (10 mg kg−1 d−1), low dose interleukin (IL)‐2 (25 000 IU/d), and control (saline water). Drugs were treated for 12 weeks. LBP.L significantly reduces the salivary gland inflammation compared with the control group (histological score p LBP.L vs Control = 0.019; foci number: p LBP.L vs Control = 0.038). LBP.L also remarkably reduces the effector follicular helper T (Tfh) cells and the CD4+IL‐17A+ helper T (Th17) cells in both spleen and cervical lymph node (cLN) cells. Additionally, the ratios of regulatory T cell (Treg)/Tfh cells and Treg/Th17 cells are substantially increased in mice treated with LBP.L in both spleen and cLNs. LBP also inhibits Th17 and Tfh cells and markedly increases the Treg/Tfh ratio in human peripheral blood mononuclear cells. Conclusion LBP.L inhibits the progression of pSS in mice, associated with modulation of T cell differentiation.

show abstract